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Summary 
Live attenuated and killed whole cell vaccines offer a promising vaccination 
strategy against tuberculosis. A number of whole cell vaccine candidates, 
based on recombinant BCG, attenuated Mycobacterium tuberculosis, or 
related mycobacterial species are in various stages of preclinical or clinical 
development. In this review, we discuss the vaccine candidates and key 
factors shaping the development pathway for live and killed whole cell 










Development of vaccines against many human pathogens was traditionally 
based on attenuation or inactivation of the pathogenic organism. This 
approach has been very successful and many live attenuated vaccines confer 
highly durable immune responses that provide protective immunity for 
decades [1]. 
Live attenuated or killed whole cell vaccines (WCV) against mycobacteria also 
have potential advantages over protein–adjuvant formulations and 
recombinant viral-vectored constructs for vaccination against tuberculosis 
(TB). This is supported by a plethora of evidence of vaccination against TB 
with Bacille Calmette Guerin (BCG), an attenuated strain derived from 
Mycobacterium bovis originally isolated from cows. BCG is typically the most 
protective vaccine against Mycobacterium tuberculosis in experimental animal 
models. A number of human trials of BCG also show partial vaccine efficacy 
against TB [2, 3]. The advantages of WCV over protein-adjuvant formulations 
and viral-vectored constructs are hypothesized to be due to their broad 
antigen composition, which includes the (almost) complete protein repertoire, 
lipids, carbohydrates and other moieties that may be antigenic and induce 
donor unrestricted T cell responses, B cell responses and possibly also NK 
and ILC responses. Live WCV also possess an ability to induce long-lasting 
memory immune responses, probably related to their restricted persistence or 
replication in vivo, as typified by other whole cell vaccines (e.g. measles, 
yellow fever, polio). In addition, BCG vaccination may have a general positive 
effect on mortality due to other diseases, at least in resource-limited countries 










cells after BCG vaccination, a process referred to as “trained immunity” [5]. It 
is most likely that these positive effects are also induced by live WCV. 
Live attenuated TB vaccines thus offer a promising vaccination strategy 
against TB, and a number of vaccine candidates based on recombinant BCG 
and attenuated M. tuberculosis are in preclinical or clinical development. To 
be considered for licensing the WHO recommends that these vaccine 
candidates will need to be either on their own or as heterologous boosts of 
BCG, i/ safer than BCG or ii/ at least as safe as BCG and more efficacious 
than BCG in a prophylactic setting. Therefore, it is expected that various new 
WCV candidates will target different indications: (1) WCV safer than BCG will 
primarily target neonates, since BCG is already (partially) protective in this 
population; (2) a WCV developed as a booster of BCG and to be used in 
adolescents will have to fill particular booster conditions, e.g. inducing 
tolerable and/or acceptable adverse events after secondary or tertiary booster 
administration; (3) a WCV expressing latency antigens is needed for 
adolescents and young adults with latent M. tuberculosis infection (LTBI); and 
(4) a highly attenuated or even killed WCV may be particularly interesting for 
therapy in adjunct to chemotherapy, especially for immunocompromised 
individuals such as those with AIDS. 
Here we review recent progress in clinical and preclinical development of 











Lessons from VPM1002 and MTBVAC, the most clinically advanced WCV 
The recombinant BCG, VPM1002, is at the most advanced stage of clinical 
development. VPM1002 expresses listeriolysin (LLO, encoded by the gene 
hly in Listeria monocytogenes), which is known to perforate the phagosomal 
membrane and is biologically active at a pH of 5.5 [6]. Optimal biological 
activity of LLO in the phagosome containing VPM1002 is achieved by deletion 
of the urease C subunit-encoding gene (ureC), which functions to reduce 
acidification of the phagosomal compartment. VPM1002 is therefore designed 
to allow enhanced release of BCG-derived antigens into the cytosol and 
increased apoptosis and xenophagy of host cells in vitro [7, 8]. After extensive 
preclinical development VPM1002 successfully completed two phase I trials 
(NCT 00749034 [9, 10] and NCT 01113281) and one phase IIa trial in infants 
(NCT 01479972), which show that it is safe and immunogenic in 
adolescents/adults and infants. It is currently being assessed in large cohorts 
of newborns from HIV+ and HIV- mothers (NCT 02391415). VPM1002 has 
been found to be highly efficacious, with an excellent safety record in 
preclinical models as compared to BCG [7]. In a mouse model, VPM1002 
induced central memory T cells to a greater degree than BCG and when 
adoptively transferred, this central memory cell population provided protection 
with high efficiency [11]. In vitro studies indicate that VPM1002 induces 
increased apoptotic and xenophagic events, which may underlie the 
promising safety and efficacy record to date [8]. More recently, it has also 
been shown to be highly effective as post-exposure vaccine in an 
experimental mouse model of LTBI (M. Gengenbacher et al. Submitted). 










TB patients who had completed drug treatment, expected with a risk of 
relapse in the order of 10%. Hence, this is a high-risk group allowing 
assessment in study groups of 1,000-2,000 individuals. 
MTBVAC is a live rationally attenuated derivative of the M. tuberculosis isolate 
MT103, which belongs to lineage 4 (Euro-American), one of the most 
widespread lineages of M. tuberculosis. MTBVAC contains all the genes 
present in M. tuberculosis strains commonly transmitted between humans by 
the aerosol route, including the genes that are deleted in M. bovis and BCG. 
MTBVAC contains two independent stable deletion mutations in the virulence 
genes phoP and fadD26. These deletions were generated in the absence of 
antibiotic resistance markers, fulfilling the Geneva consensus requirements 
for progressing live mycobacterial vaccines to clinical trials [12]. PhoP is a 
transcription factor that controls expression of 2% of the M. tuberculosis 
genome, including production of immunomodulatory cell-wall lipids and early 
secretory antigenic target (ESAT)-6 secretion [13]. Deletion of fadD26 leads to 
complete abrogation of synthesis of the virulence surface lipids phtiocerol 
dimycocerosates (PDIMs) [14]. Extensive preclinical studies demonstrated 
adequate attenuation and safety of MTBVAC comparable to BCG, with 
superior immunogenicity and efficacy against M. tuberculosis [12, 15]. A first-
in-human MTBVAC clinical trial was recently completed successfully in 
healthy adults in Lausanne, Switzerland (NCT02013245) [16]. In this trial, 
when MTBVAC was given at the same dose as BCG (5x10⁵ CFU), there were 
more responders in the MTBVAC group than in the BCG group, with a greater 










has the limitation, as a phase I first in-human trial, that the secondary 
objective (immunogenicity) was not powered for statistical analysis. 
Nevertheless, MTBVAC is the first live-attenuated M. tuberculosis vaccine to 
enter clinical trials and to date has shown a comparable safety profile to BCG 
[16]. A notable finding in the first trial was the absence of ESAT-6 and CFP-
10-specific T cell responses at the end of the study [16], suggesting that 
interferon- release assays (IGRAs) could be utilized as study endpoints in 
future efficacy trials to test efficacy against M. tuberculosis infection. The 
immunogenicity data show that MTBVAC is at least as immunogenic as BCG. 
Altogether these data supported the advanced clinical development in high-
burden countries where TB is endemic. A dose-escalation safety and 
immunogenicity study to compare MTBVAC to BCG in newborns with a safety 
arm in adults is currently ongoing in South Africa (NCT02729571). 
Other WCV candidates 
Other WCV candidates have completed preclinical development and entered 
or are about to enter clinical trials in humans. They include candidates to be 
used either as therapeutic or preventive vaccines. 
Therapeutic vaccine candidates 
RUTI is a polyantigenic liposomal vaccine made of detoxified, fragmented M. 
tuberculosis cells. It is targeted for the prevention of active TB in subjects with 
LTBI. A phase IIa clinical trial was completed in 2014 in South Africa [17]. 










tolerability and immunogenicity in HIV-infected and -uninfected subjects with 
latent M. tuberculosis infection after completion of one-month isoniazid 
treatment before vaccination. RUTI was well tolerated and its immunogenicity 
profile suggested a single injection of one of the highest doses might be 
optimal and sufficient, which will be tested in future trials. New trials are being 
planned, including evaluation of the efficacy of RUTI in specific populations 
such as patients with MDR-TB (C. Villaplana and P.J. Cardona, Personal 
communication). 
M. indicus pranii preparation was found to have potential effects against TB 
when used as an aerosol-delivered adjunct to chemotherapy in animal 
models, including guinea pigs [18]. However, in a recent phase III clinical trial 
in patients with TB pericarditis M. indicus pranii vaccination had no 
immunotherapeutic effect either alone or adjunctive to prednisolone [19]. 
Based on clinical evidence that this vaccine candidate can modulate 
immunopathology in sepsis [20], it is currently being assessed as an 
immunotherapeutic agent in a phase IIb trial in patients with severe sepsis 
(ClinicalTrials.gov reference, NCT02330432). 
Vaccine preparations of the non-tuberculous mycobacteria, M. vaccae and M. 
obuense, have also been extensively developed in preclinical studies and 
clinical trials. Killed M. vaccae was studied for use as an immunotherapeutic 
agent against leprosy and TB [21]. Killed M. vaccae as well as a M. vaccae 
lysate, made by a press method, have been assessed as adjunct therapy to 










persons. Two meta-analyses by Yang et al. [22, 23] suggested that M. vaccae 
therapy led to moderate improvements in sputum conversion and 
radiographical appearances. A phase III trial of the lysate preparation of M. 
vaccae is currently underway in China (personal communication, Ann 
Ginsberg, Aeras). 
Heat-killed preparations referred to as SRL172 and DAR-901, initially thought 
to be M. vaccae but recently identified as M. obuense, have also been tested 
in numerous trials [24, 25]. One such a M. obuense preparation was tested as 
a booster in a phase III trial known as the Dar-Dar trial in BCG-vaccinated and 
HIV-infected adults in Tanzania [26]. The data suggest that multiple-dose 
administration of inactivated, whole cell M. obuense may prevent HIV-
associated TB. The conclusions of this trial need to be confirmed in further 
trials; a phase I of the DAR-901 candidate is currently underway (personal 
communication, Ann Ginsberg, Aeras). 
Preventive live vaccine candidates 
Many other live WCV candidates are in the preclinical development pipeline, 
some with very promising results (Table 2). For instance, a BCG mutant 
inactivated in zmp1, a gene involved in inflammasome inhibition, appeared 
more immunogenic and safer than BCG in mice and is more protective than 
BCG in mice and guinea pigs [27]. This candidate is poised to enter phase I 
clinical trial soon (P. Sander, Personal communication). Other attenuated M. 
tuberculosis strains, inactivated in the transcriptional regulator SigH [28] or in 










biosynthesis respectively, amongst others [29, 30] are also in preclinical 
development and may enter phase I trials in the future. 
Safety of WCV 
Safety of live WCV is a critically important consideration. The safety concerns 
are exemplified by the observation that BCG, a highly attenuated live vaccine 
that has been given to ca. 4 billion people, can cause disseminated disease in 
immunocompromised persons. The inherently difficult question for WCV is the 
optimal degree of attenuation. According to WHO recommendations two 
independent genetic inactivations must be made in an M. tuberculosis-based 
vaccine candidate before it can enter clinical trials [31]. Highly attenuated 
strains, completely incapable of in vivo replication, are most likely very safe, 
but might fail to induce sufficient immunity for long-term protection. For 
example, a M. tuberculosis pantothenate auxotrophic mutant was found much 
safer and as protective as BCG in mice [30]; whether strains of this nature 
confer long-term protection against TB remains to be evaluated in appropriate 
experimental settings. The BCG-Δzmp1 mutant [27] and VPM1002 (see 
above) are good examples of WCV that appear safer and more immunogenic 
and protective than BCG, at least in animal models. 
On the other hand, less attenuated strains may persist for longer periods of 
time in vivo and therefore be highly immunogenic, but may also be associated 
with unac eptable adverse events. For example, a phase I clinical safety trial 
of a recombinant BCG vaccine, which expressed perfringolysin, Ag85A, 
Ag85B, and Rv3407, had to be terminated because two vaccine recipients 










Given the rich literature on safety and efficacy of BCG, it is ideal that studies 
of WCV candidates be performed with BCG as a comparator, to allow 
comparison of adverse events between the WCV candidates with BCG. 
Which animal models are preferred for preclinical WCV studies? 
A remarkable range of animal species have been utilized in TB vaccine 
research, including mice, guinea pigs, rabbits, mini pigs, badgers, cattle, and 
rhesus or cynomolgus macaques. A recent development in the TB vaccine 
community is a renewed emphasis on more stringent preclinical data about 
vaccine efficacy. Further, the Bill and Melinda Gates Foundation has 
communicated that significant vaccine efficacy in non-human primates is a 
prerequisite for their support of late-phase human trials. In light of this 
background, selection of an appropriate animal model and study design of 
animal experiments is important. Different approaches and species may be 
required for efficacy testing and in-depth immunological studies of WCV in 
animal models. For example, guinea pigs may be suitable for the former, 
whereas the virtually unlimited immunological reagents and genetic 
approaches for murine experimentation may encourage mechanistic 
immunological studies in mice. In light of the clear differences in BCG efficacy 
between unsensitized and sensitized persons [33], a good animal model for 










Can WCV be used as heterologous boosts of childhood BCG 
vaccination? 
A large number of human studies suggest that homologous boosting of 
childhood BCG vaccination with BCG does not provide additional benefit [34]. 
Although it must be acknowledged that none of these studies systematically 
optimized the interval between administrations of BCG, or any other 
parameters of the homologous prime-boost protocol, it is generally believed 
that revaccination with BCG is inefficient. It remains possibe that BCG 
revaccination in humans can be optimised to achieve greater efficacy, as 
supported by a number of studies of homologous BCG revaccination in cattle, 
deer and wild pigs, which have shown enhanced efficacy over single BCG 
[35-37]. Importantly though, BCG revaccination is not associated with major 
safety concerns in these studies. A recent study in tuberculin skin test (TST)+ 
adults also reported that BCG-revaccination was safe and well tolerated and 
that injection site reactogenicity was similar to that of primary BCG 
vaccination [38]. 
If BCG revaccination itself does not confer better protection than a BCG 
prime, how can a single heterologous WCV administration before or during 
adolescence be expected to boost BCG-induced immunity? Although 
speculative at this stage, we propose that a WCV that is better than BCG as a 
prime may also be better than BCG as a boost. This speculation might also 
hold true regarding the ability of such a better WCV to overcome the 
limitations of BCG-induced protection, thought to be due to exposure to 
environmental non-tuberculous mycobacteria or to helminthic infection, for 










adolescents with TB vaccines will be more cost effective and have greater 
impact on transmission of M. tuberculosis [40]. Since BCG is the only 
currently licenced vaccine, it is likely that advancing such heterologous 
strategies to efficacy trials will require strong evidence in preclinical models. 
Selection of animal models ideal for testing such approaches is therefore an 
important issue. 
Important further considerations include selection of revaccination intervals 
(for example, short or long intervals between prime and boost), environmental 
exposure of animals, and how to define protective efficacy in animal models. 
What is the optimal administration route for WCV? 
BCG is given as an intradermal vaccination in most countries. Can efficacy of 
WCV be improved by changing the route of immunization to percutaneous, 
intramuscular, or mucosal routes (although the latter raises safety concerns 
that will need to be addressed before proceeding for clinical trials)? 
Experiments have already started in order to test the efficacy of WCV, such 
as MTBVAC and VPM1002, when delivered into the lungs via alternative 
routes, such as the intratracheal, intranasal, oral and aerosol routes. A recent 
murine study showed that BCG administered intranasally, but not 
subcutaneously, confers robust protection against pulmonary M tuberculosis 
challenge, indicating that pulmonary vaccination triggers a specific mucosal 
immune response [41]. These results demonstrate that airway delivery of 
BCG can overcome the lack of protection observed when BCG is given 
parenterally. Respiratory administration could therefore be advantageous in 
TB-endemic countries, where intradermally administered BCG has inefficient 











Many questions in the development of TB WCV remain. Much will be learnt 
from the many preclinical studies and clinical studies currently underway. It is 
critical that rare and expensive efficacy trials in humans are appropriately 
leveraged to perform exploratory studies that maximise the knowledge 
gained. 
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Table 2. WCV candidates in preclinical development 
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